Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-658

Garami, A; Zwartkruis, F J T; Nobukuni, T; Joaquin, M; Roccio, M; Stocker, H; Kozma, S C; Hafen, E; Bos, J L; Thomas, G (2003). Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Molecular Cell, 11(6):1457-1466.

[img]
Preview
PDF
433kB

Abstract

Tumor suppressor genes evolved as negative effectors of mitogen and nutrient signaling pathways, such that mutations in these genes can lead to pathological states of growth. Tuberous sclerosis (TSC) is a potentially devastating disease associated with mutations in two tumor suppressor genes, TSC1 and 2, that function as a complex to suppress signaling in the mTOR/S6K/4E-BP pathway. However, the inhibitory target of TSC1/2 and the mechanism by which it acts are unknown. Here we provide evidence that TSC1/2 is a GAP for the small GTPase Rheb and that insulin-mediated Rheb activation is PI3K dependent. Moreover, Rheb overexpression induces S6K1 phosphorylation and inhibits PKB phosphorylation, as do loss-of-function mutations in TSC1/2, but contrary to earlier reports Rheb has no effect on MAPK phosphorylation. Finally, coexpression of a human TSC2 cDNA harboring a disease-associated point mutation in the GAP domain, failed to stimulate Rheb GTPase activity or block Rheb activation of S6K1.

Item Type:Journal Article, refereed
Communities & Collections:07 Faculty of Science > Institute of Zoology (former)
DDC:570 Life sciences; biology
590 Animals (Zoology)
Language:English
Date:1 June 2003
Deposited On:11 Feb 2008 12:17
Last Modified:27 Nov 2013 22:19
Publisher:Elsevier
ISSN:1097-2765
Publisher DOI:10.1016/S1097-2765(03)00220-X
PubMed ID:12820960
Citations:Web of Science®. Times Cited: 517
Google Scholar™
Scopus®. Citation Count: 547

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page